3,234
Participants
Start Date
March 8, 2021
Primary Completion Date
October 15, 2021
Study Completion Date
October 15, 2021
Tyrosine Kinase Inhibitors (TKIs)
The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
Novartis Investigative Site, East Hanover
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY